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Evaluation of divided attention psychophysical
task performance and effects on pupil sizes
following smoked, vaporized and oral cannabis
administration
Matthew N. Newmeyera,b, Madeleine J. Swortwooda,c, Megan E. Taylora,
Osama A. Abulseouda, Thomas H. Woodwardd and Marilyn A. Huestisa,e*
ABSTRACT: Establishing science-based driving per se blood Δ9-tetrahydrocannabinol (THC) limits is challenging, in part because
of prolonged THC detection in chronic, frequent users. Therefore, documenting observable signs of impairment is important for
driving under the influence of drugs. We evaluated frequent and occasional cannabis smokers’ performance on the modified
Romberg balance, one leg stand (OLS), and walk and turn (WAT) tasks, and pupil size effects following controlled placebo
(0.001% THC), smoked, vaporized and oral (6.9% [~50.4mg] THC) cannabis administration. Significant effects following inhaled
doses were not observed due to delayed tasks administration 1.5 and 3.5h post-dose, but significant impairment was observed
after oral dosing (blood THC concentrations peaked 1.5–3.5 h post-dose). Occasional smokers’ odds of exhibiting ≥2 clues on the
OLS or WAT following oral dosing were 6.4 (95% CI 2.3–18.4) times higher than after placebo, with THC and 11-hydroxy-THC
blood concentrations individually producing odds ratios of 1.3 (1.1–1.5) and 1.5 (1.3–1.8) for impairment in these tasks,
respectively. Pupil sizes after oral dosing under the direct lighting condition were significantly larger than after placebo bymean
(SE, 95% CI) 0.4 (0.1, 0.2–0.6) mm at 1.5 h and 0.5 (0.2, 0.2–0.8) mm at 3.5h among all participants. Oral cannabis administration
impaired occasional cannabis users’ performance on the OLS and WAT tasks compared to placebo, supporting other reports
showing these tasks are sensitive to cannabis-related impairment. Occasional smokers’ impairment was related to blood THC
and 11-hydroxy-THC concentrations. These are important public health policy findings as consumption of edible cannabis
products increases. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Keywords: cannabis; Drug Evaluation and Classification Program; modified Romberg balance; one leg stand; walk and turn; pupil size;
performance; edibles
Introduction
Cannabis prevalence among US weekend night-time drivers
increased 48% from 2007 to 2013–2014 (Berning et al., 2015).
Increasing cannabis use among drivers poses a public health and
safety risk due to an increased crash risk (Asbridge et al., 2014;
Hartman & Huestis, 2013; Li et al., 2012; Ramaekers et al., 2004).
Establishing science-based per se limits for blood Δ9-tetrahydro-
cannabinol (THC) is difficult, in part, due to prolonged THC detec-
tion following chronic, frequent intake; THC was detected at
0.3μg l1 in some chronic frequent cannabis smokers’ blood
30days after initiation of abstinence (Bergamaschi et al., 2013). In
other frequent cannabis users, blood THC was >1μg l1 up to
6.5 days after last reported use, and in some, THC was ≥5μg l1
(one currently implemented per se cutoff ) up to 5.4 days after last
reported use (Odell et al., 2015). Another contributing factor is that
THC rapidly distributes from blood. After vaporized cannabis
administration to occasional-to-moderate smokers, maximum
blood THC concentrations decreased a median 73.5% within
0.5 h post-dose and 90.3% by 1.4h, with median concentrations
<5μg l1 by 3.3 h post-dose (Hartman et al., 2016d). Rapid
decreases were similarly observed in frequent smokers (Newmeyer
et al., 2016), quickly returning to baseline concentrations. These
factors contribute to the difficulty in relating blood THC concentra-
tions to impairment.
When an officer stops an individual suspected of driving under
the influence (DUI), standardized field sobriety tests (e.g., horizontal
gaze nystagmus, walk and turn [WAT] and one leg stand [OLS]) are
performed, leading to arrest if impairment is observed. If
impairment based on standardized field sobriety test observations
is not consistent with the suspect’s blood alcohol concentration or
the officer is unsure of naming an impairing agent, a drug
recognition expert (DRE) evaluation may be requested. The DRE
utilizes a standardized 12-step procedure combining physiological,
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psychophysical and observational evidence to form an opinion on
which drug class(es) (central nervous system depressants, central
nervous system stimulants, hallucinogens, dissociative anesthetics,
narcotic analgesics, inhalants and cannabis) contribute(s) to the
impairment.
Smoked cannabis can produce impairment on tasks associated
with driving performance (Ramaekers et al., 2006), with an
approximate twofold increase in risk of involvement in a motor
vehicle crash (Hartman & Huestis, 2013); however, partial tolerance
to some impairing effects was demonstrated in frequent cannabis
smokers (Desrosiers et al., 2015; Hart et al., 2001; Ramaekers et al.,
2009; Theunissen et al., 2012). Following cannabis vaporization, an
alternative inhalation route, occasional-to-moderate cannabis
smokers demonstrated increased standard deviation of lateral
position (lane weave), similar to impairing alcohol concentrations,
with during-drive blood THC ≥8.2μg l1 (Hartman et al., 2015),
while also demonstrating slower driving and greater headway
(distance relative to a lead vehicle) (Hartman et al., 2016a).
Following various oral cannabis doses, the percentage of time
spent in a pre-defined lane on a computerized tracking task was
decreased (Ménétrey et al., 2005). In another investigation, oral
dronabinol increased the standard deviation of lateral position
and time to speed adaptation in occasional smokers (Bosker
et al., 2012a). Oral THC produces delayed subjective and
impairing effects and these are dependent on administered
dose(s). Additionally, lower THC concentrations occur following
oral dosing compared to inhaled cannabis. There is great
uncertainty in THC content of commercial edible cannabis
products, with 23% and 60% of tested products under-labeling
and over-labeling THC content, respectively (Vandrey et al.,
2015). This is concerning as cannabis-containing edibles also are
taken as medical cannabis and doses may be subtherapeutic,
and because consumers may experience adverse effects if doses
are larger than reported.
We sought to evaluate frequent and occasional cannabis users’
performance on tasks from the Drug Evaluation and Classification
Program (DECP) following controlled administration of placebo,
smoked, vaporized and oral cannabis; chosen tasks previously
demonstrated sensitivity to cannabis-related impairment (Bosker
et al., 2012b; Heishman et al., 1996, 1998). The complex full study
timeline only permitted psychophysical examinations at 1.5 and
3.5h. Improving interpretation of observed DUI of drugs (DUID)
impairment signs is critical, given the difficulty in establishing
appropriate science-based per se THC limits for both occasional
and frequent cannabis users and establishing relevant public
health policy and legislation.
Materials and methods
Participants
Adults 18–50 years old provided written, informed consent to
participate in this National Institute on Drug Abuse (NIDA)
Institutional Review Board-, Federal Drug Administration- and Drug
Enforcement Administration-approved study (Newmeyer et al.,
2016; Swortwood et al., 2016). Inclusion criteria were the average
self-reported cannabis intake frequency≥ 2× per month but <3×
per week (occasional smokers), or ≥5× per week (frequent smokers)
for the previous 3months, and a positive urine cannabinoid screen
(frequent smokers). All participants underwent extensive medical
and psychological evaluations before the study inclusion; anyone
physically dependent on any drug other than cannabis, caffeine
or nicotine or who could or would not discontinue use of contrain-
dicated medications during the study were excluded.
Study design
This was a randomized, double-blind, placebo-controlled,
crossover, double-dummy study. Participants entered the secure
research unit ~19h before dosing to preclude acute intoxication.
Cannabis cigarettes were supplied from NIDA Research
Technology Branch. Active (0.734±0.05g) and placebo (0.713
±0.05 g) cigarettes contained 6.9± 0.95% (~50.6mg) and
0.001±0.000% THC, respectively. Oral cannabis doses were
prepared per Duncan Hines® Double Fudge cake-like brownie
instructions. The contents of an active or placebo cigarette were
ground, baked for 30min at 121°C in aluminum foil, and mixed
into equal portions of batter in a muffin tin. Following baking,
individual doses were stored frozen, but allowed to thaw
refrigerated overnight before dosing.
The study timeline is summarized in Fig. 1. Throughout four
dosing sessions, participants were administered one active or
placebo cannabis-containing brownie followed by one active or
placebo cigarette or one active or placebo vaporized ground
cannabis dose (210°C; Volcano® Medic; Storz & Bickel, Tuttlingen,
Germany). Only one active dosewas administered per session. Par-
ticipants consumed the oral and smoked or vaporized dose ad
libitum for 10min. Frequent smokers remained on the unit 72 h
post-dose and left the unit for ≥72h between sessions to minimize
withdrawal symptoms. Occasional smokers remained on the unit
54h post-dose, but could stay or leave between sessions if dosing
was no more frequent than self-reported intake. Previous
controlled cannabis studies informed our choice of time between
sessions for occasional cannabis users (Desrosiers et al., 2014;
Schwope et al., 2011). Blood was collected on admission (if
applicable) and at baseline of every session for proper result
interpretation.
Psychophysical evaluations
Psychophysical tests challenge the ability to divide attention
between remembering directions while performing a physical
Figure 1. Summary of study procedures, including times of placebo
(0.001% THC) or active (6.9% THC, ~50.6mg) smoked and vaporized
(inhaled) and oral cannabis administration, psychophysical exams
(modified Romberg balance, one leg stand, and walk and turn), and eye
exams. THC, Δ9-tetrahydrocannabinol.
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task. A certified DRE trained research staff on administering modi-
fied Romberg balance (MRB), OLS and WAT tests. Descriptions of
the tasks and the impairment clues or observations are summa-
rized in Table 1. Observation of ≥2 clues is the DRE “impairment”
criteria, originally validated for 0.08% blood alcohol concentrations
(Stuster, 2006). Owing to constraints on the busy study timeline
and the required time for the psychophysical task presentation,
the tests were administered 1.5 and 3.5 h post-dose.
Eye examinations
The cannabis’ effects on pupil size and lack of convergence (LOC;
inability to cross the eyes while focusing on a stimulus slowly
approaching the bridge of the nose) were examined with the
DAX™ Evidence Recorder (Ocular Data Systems LLC, Pasadena,
CA, USA). The DAX recording device enables pupil size observation
and video recording in room light (RL), near-total darkness (NTD)
and direct light (DL). The goggle-like frame is placed against the
participants’ face and a pupilometer is centered between the eyes
for measurement. After recording RL pupil size, a light-blocking
cover was placed on the device to produce NTD, and an infrared
camera enabled NTD pupil size measurement. A built-in light
was shown separately into each eye for pupil measurement under
DL. The cover and pupilometer were removed to evaluate LOC. Eye
examinations were performed at baseline (1.5 h) and 0.25, 1.5,
3.5 and 5h post-dose.
Data analysis
Differences in demographic data between groups were evaluated
with independent samples t-tests with SPSS® Statistics 20 for
Windows (IBM Corp., Armonk, NY, USA). Differences in participants’
estimation of 30 s during the MRB were analyzed via repeated-
measures ANOVA; the Greenhouse–Geisser correction was utilized
for sphericity violations. Between session differences in body sway
in either direction during the MRB (defined here as any sway ≥1″)
were evaluated by generalized estimating equations (GEE) with a
binomial probability distribution, logit link function and a first-
order autoregressive (AR(1)) correlation matrix. Differences in a
number of observed clues during the OLS andWAT were analyzed
by GEE but with a Poisson distribution and log link function.
Participants were categorized as “impaired” if the number of clues
exhibited during the OLS or the WAT was ≥2 (originally validated
“impairment” criterion for 0.08% blood alcohol concentrations;
Stuster, 2006). Differences in participants’ categorization were
analyzed via GEE as for body sway. In each analysis, effects of
dosing session, time and smoking group were analyzed to find
the best fit model. When possible, blood cannabinoid concentra-
tions and relevant interactions were fit to themodel instead of cat-
egorical dosing session. Finally, differences in pupil sizes between
sessions were evaluated via repeated-measures ANOVA as for MRB
time estimation; if significant dose × time interactions were ob-
served, post-hoc tests comparing dosing sessions at each time
point were conducted with a Bonferroni correction. Pupil sizes also
were modeled with linear mixed models with dosing session and
time set as repeated measures (AR(1) covariance structure); blood
cannabinoid concentrations were included as fixed or random
effects to best fit the model. Owing to differences in cannabinoid
pharmacokinetics between routes (Newmeyer et al., 2016), inhaled
and oral data were compared against placebo separately. In all
analyses, statistical significance was attributed to P< 0.05.
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Results
Participants
Table 2 summarizes demographics for 11 frequent and nine
occasional cannabis smokers (ages 19–46 years, 75% male, 75%
African American). Participants were in good physical health
without any clinically significant electrocardiogram abnormalities,
or histories of mental illness or clinically significant cannabis
adverse events. Additionally, oral fluid screening tests conducted
on admission and at baseline were all negative for other drug
classes (amphetamine, benzodiazepines, cocaine, methadone,
methamphetamine and opioids). Participant K was recruited as
an occasional cannabis smoker, but reclassified as a frequent
smoker when baseline THC and metabolite concentrations were
consistent with published frequent smoker data (Desrosiers et al.,
2014; Schwope et al., 2011). Participant H reported last use
~10days before session 1, despite self-reporting smoking five
times a week during screening; the participant reported smoking
within 0.6–18.7 h of subsequent session admission. Occasional
smokers began smoking at a significantly older age, smoked on
a significantly fewer number of days out of the previous 14 and
smoked significantly less per smoking occasion.
Blood cannabinoid concentrations
Table 3 summarizes THC and 11-hydroxy-THC (11-OH-THC) blood
cannabinoid data collected 1.5 and 3.5h post-dose. Median
percentage decreases from maximum concentrations (Cmax) after
smoking or vaporization were large (≥93.7%) in both groups.
Frequent smokers’ decreases were less than occasional smokers
were, and frequent smokers had greater THC concentrations
than occasional smokers 1.5 and 3.5h post-dose. Both frequent
and occasional smokers’ blood THC concentrations were
greater at 1.5 and 3.5h after oral dosing than after inhaled
doses due to a longer absorption phase compared to inhaled
Table 2. Demographic data and cannabis smoking histories for 11 frequent and nine occasional smokers
Participant Sex Age
(years)
Race and
ethnicitya
BMI
(kg m2)
Age at
first useb
Lifetime
years
smokedb
Cannabis
intake
frequencyb
Time between
last use and
admissionc
Number of
days used
in last 14c
Average joint
equivalents
per smoking
occasionc
Frequent smokers
A M 21 AA 26.5 16 5 Daily 17.2 h 14 5
B M 22 AA 31.0 15 7 Daily 19.3 h 10 4
C M 19 AA 19.8 13 6 Daily 18.7 h 14 4
D F 23 AA 31.9 13 10 Daily 7.9 h 14 10
E M 38 AA 32.2 12 26 Daily 2.4 h 14 15
F F 29 AA 31.0 11 18 Daily 1.9 h 14 20
G M 38 AA 22.0 16 22 Daily 2.1 h 14 7
H M 34 AA 23.0 14 20 5× a week 239.7 hd 2d 2d
I M 21 AA 25.0 11 10 Daily 0.7 h 14 5
J M 25 AA 19.0 13 12 5× a week 5.8 h 14 2
K M 31 AA 16.8 15 16 2–3× a weeke 5.1 he 4e 2.5e
Mean 27.4 25.3 13.5* 13.9 8.4 h 13.6* 8.0*
SD 6.9 5.6 1.8 6.9 7.8 h 1.3 6.0
Median 25.3 25.0 13.0 12.3 5.8 h 14.0 5.0
Occasional smokers
L M 24 AA 36.3 17 7 2× a month 1.4 days 3 2
M M 21 AA 23.0 13 8 2× a week 0.7 days 4 2
N M 25 W 24.2 21 4 2× a week 13.0 days 1 3
O M 40 W 28.3 18 22 2× a week 30.7 days 0 2
P F 46 AA 31.0 26 20 2× a week 0.4 days 4 4
Q M 33 AA 30.7 16 17 2× a month 22.8 days 0 3
R F 22 W 22.0 16 6 2× a week 1.7 days 4 1
S F 22 W 23.0 14 8 2× a week 1.1 days 10 2
T M 31 W 21.7 22 9 1–2× a week 1.8 days 2 2
Mean 29.4 26.7 18.1* 11.3 8.2 days 3.1* 2.3*
SD 8.6 5.1 4.2 6.3 11.4 days 3.1 0.9
Median 24.9 24.2 17.0 8.5 1.7 days 3.0 2.0
aAA, African American; W, white.
bData collected during screening.
cData collected on admission to session 1.
dSelf-reported data on admission inconsistent with data received at screening. Data excluded from statistics.
eSelf-reported data inconsistent with biological sample concentrations. Data excluded from statistics.
* Significant difference between groups (P< 0.05).
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routes (time of Cmax [tmax] 2.5 [1.5–3.5] h). 11-OH-THC concen-
tration percentage decreases at 1.5 and 3.5h after inhaled
doses also were high (≥69.5%), and 11-OH-THC concentrations
at both time points were greater after oral compared to in-
haled cannabis.
Psychophysical examinations
Overall, 158 tests (87 from frequent, 71 from occasional smokers)
were conducted. Summaries of participants’ performance are
presented in Table 4. No significant effects on participants’ MRB
30 s estimations were observed. A wide range of estimates was
observed, with 20.0–31.6% <30 s, 0.0–20% equal to 30 s, and
55.0–80% >30 s. Sway ≥1″ in any direction was observed in 65.0,
87.5, 65.0 and 53.8% of tests (all participants and 1.5 and 3.5 h
combined) following placebo, smoking, vaporization and oral
dosing, respectively. The odds ratio (OR [95% CI]) of sway at either
time point following smoking compared to placebo was 3.8
(1.5–9.5). There were no significant differences in sway after
vaporization or oral dosing compared to placebo. Cannabis
produced minimal impairment on the MRB task, with only smoked
cannabis associated with increased sway.
The number of observed clues during the OLS and WAT in all
participants at both time points are depicted in Fig. 2. No time
effect was observed in any analysis, so data from both time points
were combined. Oral cannabis produced an incidence rate for
number of observed clues during the OLS 1.99 (1.06–3.71) times
that following placebo. For the WAT, the incidence rate for
observed clues was 1.60 (1.13–2.26) times higher after oral canna-
bis compared to placebo. Only oral cannabis produced significant
increases compared to placebo in the number of observed clues
on the OLS and WAT tasks.
Participants were grouped based on their performance on the
OLS and WAT, with those who exhibited ≥2 clues on either test
classified as “impaired.” Significant overall effects of oral cannabis
and an interaction with use history were observed; therefore,
data from frequent and occasional smokers were analyzed
separately. Frequent and occasional smokers classified as
“impaired” in each dosing session are presented in Fig. 3. Occa-
sional smokers’ odds of being “impaired” following oral dosing
were 6.43 (2.25–18.40) times higher after placebo. No significant
differences between sessions were observed in frequent smokers.
Oral cannabis significantly increased occasional smokers’ odds of
being impaired on either the OLS or WAT tasks compared to
placebo, while active cannabis did not significantly affect
frequent smokers’ odds.
When modeling blood THC and 11-OH-THC concentrations to
participants’ classification of “impaired,” significant concentration
× group interactions were observed; therefore, occasional and
frequent smokers were analyzed separately. Model parameters
are summarized in Table 5 for occasional smokers only, as blood
cannabinoid concentrations did not significantly relate to frequent
smokers’ classification as “impaired.” Separate models were built
for THC and 11-OH-THC as no model with THC and 11-OH-THC
concentrations together yielded significant relationships. Time
was not a significant covariate or factor in any model. THC and
11-OH-THC were similarly associated with “impairment,” with OR
of 1.30 (1.12–1.52) and 1.50 (1.25–1.79), respectively. THC and
11-OH-THC concentration increases were significantly associated
with increased odds of occasional smokers being impaired on
the OLS or WAT tasks.
Table 4. Participants’ performance on themodified Romberg
balance, one leg stand and walk and turn tasks at 1.5 and 3.5h
after placebo, smoked, vaporized and oral cannabis (6.9% Δ9-
tetrahydrocannabinol [~50.6mg]) administration. Data are pre-
sented as median (range) for all participants (overall) and for
frequent and occasional smokers separately
Modified Romberg balance
Estimation 1.5 h
post-dose(s)
Estimation 3.5h
post-dose(s)
Overall
Placebo 34 (25–61) 34 (25–49)
Smoking 34 (26–51) 32 (24–42)
Vaporization 35 (18–52) 34 (19–51)
Oral 33 (24–49) 32 (18–39)
Frequent smokers
Placebo 34 (25–44) 34 (25–45)
Smoking 33 (26–51) 36 (26–42)
Vaporization 35 (29–52) 35 (25–42)
Oral 34 (25–49) 33 (28–39)
Occasional smokers
Placebo 34 (29–61) 34 (27–49)
Smoking 34 (26–41) 30 (24–40)
Vaporization 33 (18–46) 34 (19–51)
Oral 33 (24–38) 31 (18–39)
One leg stand
Clues observed
1.5 h post-dose
Clues observed
3.5 h post-dose
Overall
Placebo 0 (0–1) 0 (0–2)
Smoking 0 (0–2) 0 (0–2)
Vaporization 0 (0–2) 0 (0–2)
Oral 0 (0–1) 1 (0–3)
Frequent smokers
Placebo 0 (0–1) 0 (0–2)
Smoking 0 (0–2) 0 (0–1)
Vaporization 0 (0–2) 0 (0–2)
Oral 0 (0–1) 1 (0–3)
Occasional smokers
Placebo 0 (0–1) 0 (0–0)
Smoking 0 (0–2) 0 (0–2)
Vaporization 0 (0–1) 0 (0–1)
Oral 0 (0–1) 1 (0–2)
Walk and turn
Clues observed
1.5 h post-dose
Clues observed
3.5 h post-dose
Overall
Placebo 1 (0–3) 1 (0–2)
Smoking 1 (0–4) 1 (0–3)
Vaporization 1 (0–3) 1 (0–5)
Oral 2 (0–4) 1 (0–3)
Frequent smokers
Placebo 1 (0–3) 1 (0–2)
Smoking 1 (0–3) 1 (0–3)
Vaporization 2 (0–3) 2 (0–5)
Oral 2 (0–3) 1 (0–2)
Occasional smokers
Placebo 1 (0–2) 1 (0–2)
Smoking 0 (0–4) 1 (0–2)
Vaporization 1 (0–1) 1 (0–2)
Oral 2 (0–4) 2 (0–3)
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Eye examinations
Overall, 393 eye examinations (218 from frequent, 174 from
occasional smokers) were conducted. Pupil sizes in the RL and
NTD conditions were not significantly different between dosing
sessions, times or smoking groups; overall (all participants and
time points) mean (SD) pupil sizes after each dosing session are
presented in Table 6. No significant effects were observed for pupil
sizes in the DL condition following smoking or vaporization
compared to placebo, but significant dose, time and dose × time
effects were observed when comparing oral cannabis to placebo.
Post-hoc tests revealed that mean (SE, 95% CI) pupil sizes 1.5 and
3.5 h after oral dosing were 0.4 (0.1, 0.2–0.6) and 0.5 (0.2, 0.2–0.8)
mm larger, respectively. Significantly greater pupil sizes were
observed after oral cannabis only compared to placebo at 1.5
and 3.5h post-dose, within the range of tmax for participants’ THC
and 11-OH-THC concentrations.
Table 7 summarizes the results from modeling participants’
pupil sizes and blood cannabinoid concentrations. Time was not
a significant covariate or factor in any model. The best fitting
model included a random intercept to account for variance in
participants’ baseline pupil sizes. Blood 11-OH-THC concentrations
were significantly related to pupil sizes in all lighting conditions,
with increases of 0.032, 0.052 and 0.052mm unit1 increase in
11-OH-THC concentration for RL, NTD and DL, respectively. Blood
THC concentrations were a significant, but weak, covariate only
for pupil sizes in the NTD condition (b=0.008). 11-OH-THC
concentration increases were significantly associated with
increases in pupil sizes in all lighting conditions.
Figure 2. Distribution of the number of clues observed during the one leg stand and walk and turn tasks in 11 frequent and nine occasional cannabis
smokers 1.5 and 3.5 h after placebo, smoked, vaporized and oral cannabis (6.9%Δ9-tetrahydrocannabinol, ~50.6mg) administration. Observation of ≥2 clues
is the “impairment” criteria utilized by drug recognition experts, originally validated for 0.08% blood alcohol concentrations.
Figure 3. Percentage of 11 frequent and nine occasional smokers that
displayed ≥2 clues on either the one leg stand or walk and turn tasks 1.5
and 3.5 h after placebo, smoked, vaporized and oral cannabis (6.9% Δ9-tet-
rahydrocannabinol, ~50.6mg) administration.
Table 5. Effects of blood THC and 11-OH-THC concentrations on occasional smokers exhibiting ≥2 clues on the one leg stand orwalk
and turn tasks following administration of smoked, vaporized and oral cannabis (6.9% THC [~50.6mg])
b (SE) Wald χ2 (1 df ) P value OR (95% CI)
THC only
Intercept –1.342 (0.7130) 3.544 0.060 –
THC (μg l1) 0.265 (0.0778) 11.556 0.001 1.30 (1.12–1.52)
11-OH-THC only
Intercept –1.221 (0.5654) 4.666 0.031 –
11-OH-THC ( μg l1) 0.402 (0.0907) 19.650 <0.001 1.50 (1.25–1.79)
11-OH-THC, 11-hydroxy-THC; 95% CI, 95% confidence interval; b, model parameter (coefficient); df, degrees of freedom; OR, odds ratio;
SE, standard error; THC, Δ9-tetrahydrocannabinol.
Data from nine occasional cannabis smokers who performed the one leg stand and walk and turn tasks at 1.5 and 3.5 h post-dose who
were classified as either “impaired” or not (binary outcome variable). Models were built with either THC or 11-OH-THC concentrations
as the predictor variable with generalized estimating equations with a binary probability distribution and a logit link function. The
resulting equation is (in the case of blood THC, for example): logit(Y) = intercept + b[THC] × [THC], where logit(Y) = ln (Y/1 – Y) or the
log odds of being classified as “impaired.” An odds ratio is obtained by calculating eb, and is interpreted as the change in odds of
being classified “impaired” for each unit change in blood concentration. Bolded P values designate significance.
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LOC was observed at baseline and all post-dose time points in
all dosing sessions in five frequent and five occasional smokers
(50% overall), while four frequent and one occasional smoker
never exhibited LOC post-dose (25% overall); therefore, statistical
evaluations could not be performed.
Discussion
We sought to evaluate performance impairment on three
psychophysical tasks from the DECP – theMRB, OLS andWAT tasks
– and effects on participants’ pupil sizes and presence of LOC in
frequent and occasional users following placebo, smoked,
vaporized and oral cannabis administration.
Smoking is the most common cannabis administration route
and is associated with increased crash risk (Hartman & Huestis,
2013; Ramaekers et al., 2004), and exposes users to toxic pyrolytic
by-products such as carbon monoxide (Hazekamp et al., 2006).
Smokingwas deemed an inappropriate route formedical cannabis
administration (Institute of Medicine, 1999). Vaporization is an
attractive alternative route for recreational and medicinal
administration because carbon monoxide exposure is reduced
(Abrams et al., 2007), and similar THC concentrations are achieved
as found after smoking (Hartman et al., 2016b; Newmeyer et al.,
2016). Cannabis administration via vaporization is also associated
with impaired driving behavior (Hartman et al., 2015, 2016a). Oral
dosing is a popular route for recreational and medicinal cannabis,
although bioavailability is lower than after inhaled doses and
absorption is slow and erratic (Ohlsson et al., 1980). Oral cannabis
dosing is also associated with impaired driving (Bosker et al.,
2012a; Ménétrey et al., 2005). An additional concern is mislabeled
edible products (Vandrey et al., 2015), which may increase the risk
of adverse events occurring if users do not have accurate dosing
information. Additionally, the risk of psychosis after oral doses
appears to be greater based on the Colorado experience, although
the mechanism for this effect is currently unknown.
Large decreases from Cmax in participants’ blood cannabinoid
concentrations after smoking and vaporization were observed
Table 6. Pupil sizes (mm) in room light, near-total darkness,
and direct light conditions after placebo, smoked, vaporized
and oral cannabis (6.9% Δ9-tetrahydrocannabinol [~50.6mg])
administration. Data are presented as mean (SD) across all time
points for all participants (overall) and for frequent and
occasional smokers separately
Room light Near-total darkness Direct light
Overall
Placebo 4.2 (0.9) 5.0 (0.9) 3.3 (0.7)
Smoking 4.3 (0.8) 5.2 (0.8) 3.6 (0.7)
Vaporization 4.2 (0.9) 4.9 (0.9) 3.4 (0.7)
Oral 4.5 (0.9) 5.1 (0.8) 3.6 (0.8)
Frequent smokers
Placebo 4.1 (0.7) 4.9 (0.7) 3.2 (0.7)
Smoking 4.2 (0.8) 5.0 (0.7) 3.5 (0.8)
Vaporization 4.1 (0.8) 4.9 (0.7) 3.4 (0.7)
Oral 4.4 (0.8) 5.1 (0.8) 3.5 (0.9)
Occasional smokers
Placebo 4.3 (1.0) 5.2 (1.1) 3.5 (0.8)
Smoking 4.4 (0.8) 5.4 (0.7) 3.7 (0.5)
Vaporization 4.4 (1.1) 4.9 (1.1) 3.4 (0.7)
Oral 4.5 (1.0) 5.1 (0.9) 3.7 (0.6)
Table 7. Effects of blood THC and 11-OH-THC concentrations on pupil sizes under room light, near-total darkness and direct lighting
conditions following administration of smoked, vaporized and oral cannabis (6.9% THC [~50.6mg])
b SE df t P value 95% Confidence interval for b
Lower bound Upper bound
Room light
Intercept 4.308 0.182 21.186 23.667 <0.001 3.929 4.686
11-OH-THC 0.032 0.014 185.314 2.350 0.020 0.005 0.059
Subject variance in intercepts 0.593 0.203 0.004 0.302 1.161
AR1 rho 0.405 0.084 <0.001 0.228 0.555
Near-total darkness
Intercept 4.954 0.160 21.542 30.982 <0.001 4.622 5.286
THC –0.008 0.004 169.454 –2.218 0.028 –0.015 –0.001
11-OH-THC 0.052 0.018 107.815 2.862 0.005 0.016 0.087
Subject variance in intercepts 0.463 0.156 0.003 0.240 0.895
AR1 rho 0.079 0.084 0.345 –0.086 0.240
Direct light
Intercept 3.437 0.149 21.495 23.080 <0.001 3.128 3.746
11-OH-THC 0.052 0.010 180.965 4.959 <0.001 0.031 0.072
Subject variance in intercepts 0.410 0.135 0.002 0.215 0.783
AR1 rho 0.214 0.093 0.021 0.027 0.387
11-OH-THC, 11-hydroxy-THC; b, model parameter (coefficient); df, degrees of freedom; SE, standard error; t, t-statistic; THC, Δ9-
tetrahydrocannabinol.
Data from 11 frequent and nine occasional cannabis smokers. Pupil sizes were measured at baseline (1.5 h) and up to 5 h post-dose.
Only time points where blood 11-OH-THC was measurable (n=207) were included in linear mixed models; dosing session and time
were set as within-subject repeated measures. The resulting equation (in the case of room light, for example) is: pupil size =
intercept + b11-OH-THC × [11-OH-THC]. Only significant terms were included in the final model. Bolded P values designate significance.
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(73.5–100% for THC, 30.8–100% for 11-OH-THC). In contrast, the
percentage differences from THC and 11-OH-THC Cmax
(0.0–78.6% and 0.0–59.5%, respectively) after oral dosing were
lower, given the median (range) tmax for both analytes was 2.5
(1.5–3.5) h. Blood THC and 11-OH-THC concentrations at 1.5–3.5 h
were greater after oral dosing than after either inhaled dose
due to rapid absorption and distribution following inhaled
doses – leading to large percentage concentration decreases –
compared to the slow absorption and first pass metabolism fol-
lowing oral dosing, suggesting reasons why significant effects
generally occurred only when comparing oral dosing to
placebo. The timeline of administering tasks relative to the
administration route is an important consideration when
interpreting results.
Participants’ MRB 30 s estimations varied widely after all doses
with no significant dosing session, time or group effects. Although
cannabis users report an altered sense of time, our data are
inconclusive about how cannabis administration affects time
perception; 70% of time estimation studies in one review reported
overestimations, data from time production and reproduction
studies were inconclusive due to large methodological variability
and few available studies (Atakan et al., 2012). In controlled drug
administration studies in which DREs administered nearly com-
plete evaluations, time estimation was not among the variables
that best predicted the presence or absence of cannabis
(Heishman et al., 1996, 1998; Schechtman & Shinar, 2005). A
significant difference in time estimations was observed in a
comparison of toxicologically confirmed cannabis-only DRE
opinions (median [range] 29 [4–90] s) and controls (30 [20–53] s),
but time estimation was not among the optimized combination
of measures for detecting cannabis-related DECP performance
impairment (Hartman et al., 2016c).
Oral cannabis dosing significantly increased the number of clues
observed during the OLS and WAT compared to placebo.
Additionally, a significant effect of oral dosing was observed only
for occasional smokers on the observation of ≥2 OLS orWAT clues
compared to placebo. Following paced smoking of 1.74 or 2.93%
THC cigarettes, participants were significantly impaired (≥2 clues
observed) on the OLS and WAT from 5 to 105min after the
completion of smoking (Papafotiou et al., 2005). Performances
on the OLS and WAT were not affected 4.5 or 5 h after 10 or
20mg oral dronabinol dosing (Bosker et al., 2012a), but OLS
performance was impaired 2h after paced smoking of a 400μg
THC kg1 body weight cigarette with placebo alcohol (Bosker
et al., 2012b). Lack of impairment after the oral dronabinol dose
may be due to a lower dose and the timing of the test relative to
dosing. OLS (but not WAT) performance was impaired 2h after
paced cannabis smoking (Bosker et al., 2012b), where we did not
observe impairment on OLS after smoking, despite comparable
blood THC concentrations between studies. Differences in
observations may be due to comparing post-dose performance
to baseline (Bosker et al., 2012b) whereas we compared
performance at the same time between active and placebo
cannabis.
Hartman et al. (2016c) determined an optimized combination of
measures for detecting cannabis-related impairment on the DECP
– observing two of four of: ≥3 misses on the finger-to-nose task,
eyelid tremors during the MRB; ≥2 clues on the OLS; and ≥2 clues
on the WAT. The finger-to-nose task was not performed in this
study, and eyelid tremors were not observed. However, oral dosing
was shown to significantly increase the odds compared to placebo
of observing ≥2 OLS or WAT clues, which supports Hartman et al.
(2016c) that these tasks are sensitive to cannabis-related
impairment.
Logan et al. (2016) found no significant correlations between
blood THC concentrations and the number of either OLS or WAT
clues, noting that blood was collected a mean (median,
maximum) 74 (61, 225)min after arrest (Logan et al., 2016). We
observed significant effects of blood THC and 11-OH-THC
concentrations on the OR of exhibiting ≥2 OLS or WAT clues. This
is likely because in our controlled setting we could obtain blood
specimens simultaneously with testing. This is an important obser-
vation, particularly the contribution of 11-OH-THC concentrations
given it is an activemetabolite (Lemberger et al., 1973; Perez-Reyes
et al., 1972) and greater concentrationsmay be observed following
oral compared to inhaled doses (Newmeyer et al., 2016), which is a
concern as consumption of cannabis-containing edibles is
becoming increasingly popular (Schauer et al., 2016).
Participants’ pupil sizes were significantly different from
placebo only in the DL condition 1.5 and 3.5 h after oral dosing;
following placebo, mean (SD) pupil sizes were 3.3mm (0.6) and
3.4mm (0.7), respectively, and after oral cannabis 3.6mm (0.8)
and 3.8mm (0.8), respectively. These values are above the average
normal (unimpaired) value 3.0mm but still within the normal
range 2.0–4.5mm for the DL condition utilized by DREs
(International Association of Chiefs of Police, 2015). The
magnitude of these increases is small compared to other
evaluations; cannabis-positive drivers had a mean pupil size
5.4mm in RL compared to 4.3mm for controls (Logan et al.,
2016), and pupil sizes in cases were significantly greater and
outside normal ranges in all conditions compared to controls
(Hartman et al., 2016c). Given the small effect size observed
here it may be possible the administered dose was less than
what was self-administered by those arrested for DUID.
However, we did demonstrate that increases in blood 11-OH-
THC concentrations were significantly related to increases in
pupil sizes in all lighting conditions. THC concentrations were
variably related to pupil sizes. The much larger variability in
THC concentrations compared to 11-OH-THC concentrations
may have affected the ability to identify significant THC effects
(Table 3).
Finally, LOC was observed in 50% of participants at all time
points. Previously, LOC was observed in significantly more cases
compared to controls (Hartman et al., 2016c; Logan et al., 2016).
Significant increases in LOC prevalence were not observed due
to limited statistical power.
The timeline of task administration may have limited observa-
tion of significant effects following inhaled doses compared to
placebo due to the rapid decreases in cannabinoid concentra-
tions, but these data clearly demonstrate that oral cannabis
administration can impair OLS and WAT performance. Double
procedures (separate sessions for each placebo and active dose,
resulting in six total sessions) were not performed, but this was
offset by administering two doses per session where only one
was active, except in the double-placebo session, which served
as comparison for the active sessions. Baseline measures were
not collected for the DECP tasks due to constraints in the study
timeline, as this was one component of a larger clinical
investigation; however, baseline data are not available when
tests are administered by law enforcement personnel.
Additionally, only a portion of the DECP was administered,
limiting our conclusions on the utility of the overall exam in
detecting cannabis-related impairment; however, the utility of
the entire DECP was demonstrated elsewhere with actual cases,
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and optimized measures for detecting cannabis-related
impairment were observed (Hartman et al., 2016c; Logan et al.,
2016). Small sample size also possibly limited statistical power.
Strengths of the study include the within-subject, placebo-
controlled design, which allowed for the direct comparison of
the effects of different cannabis administration routes on task
performance, and the inclusion of both frequent and occasional
cannabis users. The simultaneous collection of blood specimens
was another strength; we demonstrated that performance on
these physical tasks is affected by cannabinoid concentrations,
which could not be demonstrated previously.
Conclusions
We present results of participant performance on divided
attention psychophysical tasks and eye examinations from the
DECP following controlled administration of placebo, smoked,
vaporized and oral cannabis to frequent and occasional smokers.
We demonstrated that oral cannabis administration impaired
performance on the OLS and WAT tasks compared to placebo,
supporting other data showing these tasks are sensitive to
cannabis-related impairment. Occasional smokers’ impairment
was related to blood THC and 11-OH-THC concentrations. These
are important findings as consumption of edible cannabis
products increases. Our data suggest that at these administered
doses, impairment following oral dosing was prolonged and
occurred later compared to inhaled doses; earlier testing post-
dose is needed to determine these relationships further. Because
science-based per se THC limits in DUID cases are difficult to
establish, increased importance may be placed on observable
signs for documenting cannabis-related impairment, particularly
for frequent users, as blood cannabinoid concentrations were
not significantly related to impairment. These data provide
guidance for the development of public health and safety policy
and legislation.
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